December 6, 2016
Chugai Pharmaceutical plans to enter the field of hemophilia. Emicizumab, a novel hemophilia A treatment that is injected subcutaneously once weekly and shows efficacy regardless of the presence of inhibitors (neutralizing antibodies) to coagulation factor VIII, will be its first...read more